Product Information
- 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide
- 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-
- GSK 189254A
- GSK 189254 free base
GSK189254A is a drug that is a novel, potent, and selective H3 receptor antagonist. GSK189254A has a high affinity for the H3 receptor and can be used to treat chronic diseases such as schizophrenia and Alzheimer's disease. GSK189254A has been shown to block histamine-induced increases in striatal dopamine concentration in rats. It also blocks 3-methoxyphenylacetic acid binding to the H3 receptor with an IC50 of 1 nM. GSK189254A has undergone clinical trials in humans and was found to have pharmacokinetic properties similar to other established drugs that are used for the treatment of schizophrenia.
Chemical properties
Technical inquiry about: 3D-VDB69073 GSK189254A
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.